A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate.

Trial Profile

A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Clazakizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 10 Feb 2012 Results published in the Annals of the Rheumatic Diseases.
    • 28 May 2011 Health-related quality-of-life results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 07 Nov 2010 Efficacy and quality-of-life results will be presented at the Annual Meeting of the American College of Rheumatology (ACR), according to an Alder Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top